Uptravi for Clinicians

Print Friendly, PDF & Email


UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).

Primary Endpoint: Time to First PAH Disease Progression Event in GRIPHON

Time to first disease progression event

The treatment effect was established early and maintained over the entire treatment period.

Summary of primary endpoint events:

Get Patients Started:
UPTRAVI Patient Enrollment and Support Resources

Managing Side Effects

Griphon: Selexipag Pivotal Trial

REVEAL Risk Score

Calculate the risk score for your patients and decide if you need to escalate therapy (those with intermediate or high risk). Click here.

REVEAL 2.0 Lite Cheat Sheet

Uptravi Full Prescribing Information: Package Inset

Uptravi is the only oral prostacyclin pathway therapy proven to reduce the risk of hospitalization for PAH

GRIPHON trial: Hospitalization for PAH as the first event

Hospitalization as first event up to end of treatment:

After you, as the treating healthcare professional (HCP), have made the decision to prescribe UPTRAVI, Actelion offers 2 distinct and complementary resources for UPTRAVI patients during their dose adjustment (titration) phase.

You must check “yes” on the enrollment form for each optional support resource available for your patient.


During the enrollment process, you, as the treating HCP, can choose a specific number of nurse visits or a visit during each dose change until your patient titrates to their personal dose of UPTRAVI.
Within 48 hours of your patient’s receipt of their first UPTRAVI shipment, an SP Nurse can make an in-home visit.
During these visits with your patient, the nurse can:

The information provided in the visits should reinforce information you, as the treating HCP, have given your patient.


An SP Pharmacist is available to call the patient at each dose change with UPTRAVI until the patient’s personal dose (maintenance dose) is achieved.

Important Safety Information

Please see the full data at:


Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI is contraindicated.


Pulmonary Veno-Occlusive Disease (PVOD)
Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI.


Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%).
These adverse reactions are more frequent during the dose titration phase.
Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo.


CYP2C8 Inhibitors
Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI with strong inhibitors of CYP2C8 is contraindicated.
Concomitant administration of UPTRAVI with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag and increased the exposure to the active metabolite by approximately 2.7–fold. Reduce the dosing of UPTRAVI to once daily in patients on a moderate CYP2C8 inhibitor.
CYP2C8 Inducers
Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI when rifampin is stopped.


Recommended Dosage
Recommended starting dose is 200 mcg twice daily. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.
Patients With Hepatic Impairment
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose is 200 mcg once daily. Increase by 200 mcg once daily at weekly intervals, as tolerated. Avoid use of UPTRAVI in patients with severe hepatic impairment (Child-Pugh class C).
Co-administration With Moderate CYP2C8 Inhibitors
When co-administered with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox and teriflunomide), reduce the dosing of UPTRAVI to once daily. Revert back to twice daily dosing frequency of UPTRAVI when co-administration of moderate CYP2C8 inhibitor is stopped.
Dosage Strengths
UPTRAVI tablet strengths:
200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg.

Health Care Education is Our Mission

Help us build this website!

We strive to be your front line in health care education and greatly value your perspective. Please help us improve the content of this website by sharing your comments with us here. Your input helps us create an ever-evolving site that is user-friendly and provides the most relevant and up to date information for the community.

This website does not provide medical advice.

Informational Site Only

The contents of the MedEdCenter site, such as texts, graphics, images, information obtained from sources, and other material obtained on the MedEdCenter site (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on MedEdCenter site.

Dear Health care providers, if you are using the resources of this site, please be sure you are in agreement with the content being provided for the patient and its applicability to the individual patient.

We thank our supporters that have made this entire project possible

Platinum Level:

Gold Level:

Silver Level:

We thank our supporters that have made this entire project possible

Platinum Level:

Gold Level:

Silver Level:


Patient Handout